154 related articles for article (PubMed ID: 36815280)
1. Computer-Aided Discovery of Potent Broad-Spectrum Vaccine Adjuvants.
Ma J; Wang S; Zhao C; Yan X; Ren Q; Dong Z; Qiu J; Liu Y; Shan Q; Xu M; Yan B; Liu S
Angew Chem Int Ed Engl; 2023 Apr; 62(18):e202301059. PubMed ID: 36815280
[TBL] [Abstract][Full Text] [Related]
2. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
Front Immunol; 2018; 9():2874. PubMed ID: 30619259
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor agonists as cancer vaccine adjuvants.
Jeon D; Hill E; McNeel DG
Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
[TBL] [Abstract][Full Text] [Related]
4. Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and α-Mannose as Adjuvants.
Shinchi H; Yamaguchi T; Moroishi T; Yuki M; Wakao M; Cottam HB; Hayashi T; Carson DA; Suda Y
Bioconjug Chem; 2019 Nov; 30(11):2811-2821. PubMed ID: 31560198
[TBL] [Abstract][Full Text] [Related]
5. Vaccine adjuvants to engage the cross-presentation pathway.
Lee W; Suresh M
Front Immunol; 2022; 13():940047. PubMed ID: 35979365
[TBL] [Abstract][Full Text] [Related]
6. Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates.
Zhang P; Andorko JI; Jewell CM
Biotechnol Bioeng; 2017 Feb; 114(2):423-431. PubMed ID: 27567213
[TBL] [Abstract][Full Text] [Related]
7. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
9. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
Front Immunol; 2022; 13():936129. PubMed ID: 36059502
[TBL] [Abstract][Full Text] [Related]
10. Study of Agonists of TLRs as Vaccine Adjuvants.
Mancini F; Micoli F; Rossi O
Methods Mol Biol; 2023; 2700():249-269. PubMed ID: 37603186
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
Jin JW; Tang SQ; Rong MZ; Zhang MQ
Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics.
Kaur A; Baldwin J; Brar D; Salunke DB; Petrovsky N
Curr Opin Chem Biol; 2022 Oct; 70():102172. PubMed ID: 35785601
[TBL] [Abstract][Full Text] [Related]
13. MnO
Song T; Liao Y; Zuo Q; Liu N; Liu Z
J Mater Chem B; 2022 May; 10(18):3474-3490. PubMed ID: 35403638
[TBL] [Abstract][Full Text] [Related]
14. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
Kumar S; Sunagar R; Gosselin E
Front Immunol; 2019; 10():1144. PubMed ID: 31191528
[TBL] [Abstract][Full Text] [Related]
15. Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.
Hioki K; Hayashi T; Natsume-Kitatani Y; Kobiyama K; Temizoz B; Negishi H; Kawakami H; Fuchino H; Kuroda E; Coban C; Kawahara N; Ishii KJ
Front Immunol; 2022; 13():847616. PubMed ID: 35663999
[TBL] [Abstract][Full Text] [Related]
16. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses.
Hou Y; Wang Y; Tang Y; Zhou Z; Tan L; Gong T; Zhang L; Sun X
J Control Release; 2020 Oct; 326():120-130. PubMed ID: 32585230
[TBL] [Abstract][Full Text] [Related]
19. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
